Home
Remicade

Remicade Market Share Analysis for November 2025

REMICADE® (infliximab) Official Consumer Website. See full Product & Safety Information, including Boxed Warnings.

Health > Pharmacy

Domainremicade.com

Year Founded--

Employees51 - 200

Annual Revenue$10M - $15M

Remicade

Remicade (including company regionals)

remicade.com

See more website traffic and engagement information

Remicade Revenue up to November 2025 is 10M - 15M

revenue generated by Remicade top domains

Remicade top domains revenue over 3 years

Revenue for Remicade top domains

remicade.com10M - 15M

See more with Sales Intelligence

Total visits to Remicade's top domains

Understand Remicade market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

remicade.com14.3K

See more with Sales Intelligence

Avg. visit duration in Remicade's top domains

Analyze Remicade engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

remicade.com00:02:41

See more with Sales Intelligence

Avg. pageviews on Remicade's top domains

See how Remicade keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

remicade.com2.37

See more with Sales Intelligence

Remicade top competitors by domain

Top similar sites in November 2025, ranked by their affinity

enbrel.comCompany NameEnbrelEmployees51 - 200HQUnited States, California, Thousand OaksAnnual revenue$10M - $15MTotal visits31.5KHealth > Pharmacy

Top technologies used by Remicade

These are the website technologies, by industry, used by Remicade top domains

Advertising (6)

DoubleClick

Conversion & Analytics (4)

Google Analytics

Audio Video Media (2)

VideoJS

Content Management System (2)

Drupal

More Technologies

5

See all

News & Signals from Remicade

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSimcha Therapeutics, Inc. partnered with Remicade on Jan 11th '24.This week: Myrobalan Therapeutics (MA, USA) secured US$24 million in Series A funding to develop innovative neurorestorative therapies, TG Therapeutics (NY, USA) will develop Precision BioSciences' (NC, USA) cell therapy, azer-cel, for autoimmune diseases and other indications outside of cancer, and Simcha Therapeutics (CT, USA) partnered with Janssen Biotech (CA, USA) to enhance CAR T-cell therapies using interleukin-18 (IL-18) technology.

NewsRemicade is developing multiple myeloma IVD test.Manufacturers in the Global IVD Antibodies Industry are focusing on mergers, acquisitions, collaborations and agreements such as Sebia Inc. one of the major IVD manufacturing company signed an agreement with Janssen Biotech to develop multiple myeloma IVD test.

NewsRemicade is developing CAR T-cell therapies for B-cell malignancies generation.Janssen Biotech, a subsidiary of Johnson & Johnson, has teamed up with Cellular Biomedicine Group (CBMG) to develop, manufacture and market new-generation CAR T-cell therapies for B-cell malignancies.